<DOC>
	<DOCNO>NCT00977600</DOCNO>
	<brief_summary>To determine safety tolerability single oral dos HPN-100 formulation ( GT4P-F ) GT4P active pharmaceutical ingredient ( GT4P-API ) administer healthy male subject .</brief_summary>
	<brief_title>A Study Glyceryl Tri- ( 4-phenylbutyrate ) ( GT4P )</brief_title>
	<detailed_description>A randomized , open-label , four-treatment , four-period crossover study healthy male subject receive single dose follow four treatment four separate dosing day , 7 day apart : - Oral sodium phenylbutyrate ( Buphenyl® ) equivalent 3 g/m2 4-phenylbutyric acid ( PBA ) per dose - Oral GT4P-F mole equivalent 3 g/m2 PBA per dose - Oral GT4P-API mole equivalent 3 g/m2 PBA per dose - Intravenous 10 % sodium phenylacetate plus 10 % sodium benzoate ( Ammonul® ) 2.75 g/m2</detailed_description>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<mesh_term>Phenylacetic acid</mesh_term>
	<mesh_term>Sodium Benzoate</mesh_term>
	<criteria>Subjects require fulfill follow criterion order participate study : Males age 18 45 year age Ability provide write , informed consent studyrelated procedure , ability , opinion investigator , comply requirement study Subjects good health determine medical history , physical examination , serum chemistry , hematology , urinalysis , 12 lead ECG , vital sign Weight within range 60120 kg Subjects fulfil follow criterion exclude study : Clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurologic , immunologic , psychiatric disorder ( ) , determine investigator Clinically significant abnormal laboratory value ( determine investigator ) Significant illness within 14 day prior screen Any disorder might significantly interfere absorption , distribution , metabolism , excretion drug Use prescription medication within 14 day prior screen Use dietary supplement , herbal medicine , vitamin , overthecounter medication ( ) ( exception acetaminophen ≤ 500 mg/day ) within 10 day prior first dose Positive drug abuse urine test screen predose day ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids , methadone ) Positive alcohol breath test screen predose day Donation loss blood ( 500 ml ) within 30 day prior first dosing , study Donation loss plasma within 7 day prior first dosing , study History current hepatitis carrier hepatitis B surface antigen ( HBsAg ) and/or hepatitis C antibody ( antiHC ) History acquire immunodeficiency syndrome ( AIDS ) determine HIV positive screening Use investigational drug within 12 week prior first dose Known hypersensitivity sodium phenylbutyrate similar drug Previous exposure sodium phenylbutyrate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ammonul</keyword>
	<keyword>Sodium phenylacetate</keyword>
	<keyword>sodium benzoate</keyword>
	<keyword>Buphenyl</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>HPN-100</keyword>
	<keyword>GT4P</keyword>
	<keyword>Glyceryl tri- ( 4-phenylbutyrate )</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>